Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Diabetes mellitus in chronic kidney disease: Biomarkers beyond HbA1c to estimate glycemic control and diabetes-dependent morbidity and mortality

Research output: Contribution to journalReviewResearchpeer-review

  1. Hemoglobin A1c-levels and subsequent risk of depression in individuals with and without diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Psychosocial health in people with diabetes during the first three months of the COVID-19 pandemic in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Silent atrial fibrillation detected by home-monitoring: Cardiovascular disease and stroke prevention in patients with diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Prediction of carotid intima-media thickness and its relation to cardiovascular events in persons with type 2 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Peripheral, synaptic and central neuronal transmission is affected in type 1 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Sidar Copur
  • Emine M Onal
  • Baris Afsar
  • Alberto Ortiz
  • Daniel H van Raalte
  • David Z Cherney
  • Peter Rossing
  • Mehmet Kanbay
View graph of relations

Diabetes mellitus (DM) is the leading cause of chronic kidney disease (CKD). Optimal glycemic control contributes to improved outcomes in patients with DM, particularly for microvascular damage, but blood glucose levels are too variable to provide an accurate assessment and instead markers averaging long-term glycemic load are used. The most established glycemic biomarker of long-term glycemic control is HbA1c. Nevertheless, HbA1c has pitfalls that limit its accuracy to estimate glycemic control, including the presence of altered red blood cell survival, hemoglobin glycation and suboptimal performance of HbA1c assays. Alternative methods to evaluate glycemic control in patients with DM include glycated albumin, fructosamine, 1-5 anhydroglucitol, continuous glucose measurement, self-monitoring of blood glucose and random blood glucose concentration measurements. Accordingly, our aim was to review the advantages and pitfalls of these methods in the context of CKD.

Original languageEnglish
Article number107707
JournalJournal of Diabetes and its Complications
Volume34
Issue number11
Pages (from-to)107707
ISSN1056-8727
DOIs
Publication statusPublished - Nov 2020

    Research areas

  • Chronic kidney dise, Diabetes mellitus, Glycated albumin, Glycemia, HbA1c, Monitoring, Chronic kidney disease

ID: 61379131